Suggested remit - To appraise the clinical and cost effectiveness of lusutrombopag within its marketing authorisation for treating thrombocytopenia in people with chronic liver disease needing elective surgery.
 
Status Proposed
Process STA pre-2018
ID number 1149

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
29 November 2018 The Department for Health and Social Care has asked us to carry out an appraisal of avatrombopag and lusutrombopag within their marketing authorisations for treating thrombocytopenia in people with chronic liver disease needing an elective procedure. The appraisal is expected to start in approximately mid December 2018 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early April 2019. The previous proposed Single Technology Appraisals for avatrombopag ID1105 and lusutrombopag ID1149 have now been combined and a Multiple Technology Appraisal will be undertaken as ID1520.
26 January 2018 - 23 February 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance